Harvard Apparatus Regenerative Technology, Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
HRGNStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share data)
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2026 | 2025 | |
| Product revenue | $226 | $45 |
| Operating expenses: | ||
| Cost of sales | 206 | 33 |
| Research and development | 563 | 601 |
| Sales and marketing | 18 | 10 |
| General and administrative | 1,045 | 1,071 |
| Total operating expenses | 1,832 | 1,715 |
| Operating loss | (1,606) | (1,670) |
| Other income (expense), net: | ||
| Interest income | 2 | 13 |
| Interest expense | (2) | (2) |
| Other income | 5 | — |
| Other income (expense), net | 5 | 11 |
| Net loss | $(1,601) | $(1,659) |
| Basic and diluted net loss per share | $(0.09) | $(0.10) |
| Weighted average common shares outstanding, basic and diluted | 17,580,744 | 15,918,979 |
| Comprehensive loss: | ||
| Net loss | $(1,601) | $(1,659) |
| Foreign currency translation adjustments | 4 | — |
| Comprehensive loss | $(1,597) | $(1,659) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.